Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $7.5 million.

  • Standard Biotools' Share-based Compensation rose 6209.94% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 2696.91%. This contributed to the annual value of $31.7 million for FY2024, which is 14180.45% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Share-based Compensation is $7.5 million, which was up 6209.94% from $5.4 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' Share-based Compensation peaked at $11.6 million during Q1 2024, and registered a low of $1.7 million during Q4 2022.
  • Its 5-year average for Share-based Compensation is $4.9 million, with a median of $4.3 million in 2021.
  • In the last 5 years, Standard Biotools' Share-based Compensation plummeted by 6147.15% in 2022 and then surged by 26883.74% in 2024.
  • Over the past 5 years, Standard Biotools' Share-based Compensation (Quarter) stood at $4.4 million in 2021, then crashed by 61.47% to $1.7 million in 2022, then skyrocketed by 106.72% to $3.5 million in 2023, then surged by 114.96% to $7.5 million in 2024, then grew by 0.88% to $7.5 million in 2025.
  • Its Share-based Compensation stands at $7.5 million for Q3 2025, versus $5.4 million for Q2 2025 and $9.0 million for Q1 2025.